Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

BACKGROUND: Patients with hepatocellular carcinoma (HCC) and Child–Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Khoueiry, Anthony B., Meyer, Tim, Cheng, Ann-Lii, Rimassa, Lorenza, Sen, Suvajit, Milwee, Steven, Kelley, Robin Kate, Abou-Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994237/
https://www.ncbi.nlm.nih.gov/pubmed/35397508
http://dx.doi.org/10.1186/s12885-022-09453-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994237/
https://www.ncbi.nlm.nih.gov/pubmed/35397508
http://dx.doi.org/10.1186/s12885-022-09453-z

Ejemplares similares